Dominari (NASDAQ:DOMH - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued on Thursday.
Dominari Trading Down 3.0%
Shares of DOMH traded down $0.14 during mid-day trading on Thursday, reaching $4.60. The company's stock had a trading volume of 209,992 shares, compared to its average volume of 1,264,138. The stock has a market cap of $67.36 million, a PE ratio of -1.19 and a beta of 0.59. Dominari has a 52 week low of $0.83 and a 52 week high of $13.58. The company's fifty day moving average price is $4.62 and its two-hundred day moving average price is $3.81.
Dominari (NASDAQ:DOMH - Get Free Report) last issued its earnings results on Tuesday, April 15th. The company reported $0.20 earnings per share for the quarter. Dominari had a negative return on equity of 32.89% and a negative net margin of 180.22%. The company had revenue of $6.56 million during the quarter.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Dominari stock. Renaissance Technologies LLC boosted its position in Dominari Holdings Inc. (NASDAQ:DOMH - Free Report) by 20.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 56,326 shares of the company's stock after acquiring an additional 9,400 shares during the period. Renaissance Technologies LLC owned 0.89% of Dominari worth $55,000 at the end of the most recent reporting period. Institutional investors own 42.48% of the company's stock.
Dominari Company Profile
(
Get Free Report)
Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.
See Also
Before you consider Dominari, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dominari wasn't on the list.
While Dominari currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
